Search | IOVS | ARVO Journals

Showing 1 – 20 of 26

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2023

Predicting Late Age-Related Macular Degeneration Development: Clinical Performance With Multimodal Imaging and Comparison to a Prediction Model

Kai Lyn Goh; Carla J Abbott; Sandy Clarke-Errey; Thomas G Campbell; Amy C Cohn; Dai Ni Ong; Sanjeewa S Wickremasinghe; Lauren AB Hodgson; Robyn H Guymer; Zhichao Wu

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2178.

ARVO Annual Meeting Abstract June 2021

Phase 1 Study of an Intravitreal Axitinib Hydrogel-based Implant for the Treatment of Neovascular Age-Related Macular Degeneration (nAMD)

James Gilbert Wong; Andrew Chang; Robyn H Guymer; Sanjeewa Wickremasinghe; Erin Reilly; Nicki Bell; Srilatha Vantipalli; Andrew A Moshfeghi; Michael H Goldstein

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):218.

ARVO Annual Meeting Abstract July 2019

The DiMECat Trial: A Prospective, Randomised Clinical Trial Of Intravitreous Bevacizumab vs. Triamcinolone in Patients With Diabetic Macular Oedema At The Time Of Cataract Surgery – 12 Month Results

Lyndell L Lim; Marios Constantinou; Sophie Rogers; Sukhpal Singh Sandhu; Sanjeewa Wickremasinghe; Salmaan Qureshi

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3862.

Retina November 2018

The Influence of Intravitreal Ranibizumab on Inflammation-associated Cytokine Concentrations in Eyes With Diabetic Macular Edema

PDF

Shueh Wen Lim; Esther Bandala-Sanchez; Maria Kolic; Sophie L. Rogers; Annie K. McAuley; Lyndell L. Lim; Sanjeewa S. Wickremasinghe
TAGS: cytokine, diabetic macular edema, eye, inflammation, ranibizumab, vascular endothelial growth factor a
Invest. Ophthalmol. Vis. Sci.. 2018; 59(13):5382-5390. https://doi.org/10.1167/iovs.17-23325

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2018

The DiMECat Trial: A Prospective, Randomised Clinical Trial Of Intravitreous Bevacizumab vs. Triamcinolone In Patients With Diabetic Macular Oedema At The Time Of Cataract Surgery – 6 Month Results

Lyndell L Lim; Marios Constantinou; Sophie Rogers; Sukhpal Singh Sandhu; Sanjeewa Wickremasinghe; Salmaan Al-Qureshi

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1958.

ARVO Annual Meeting Abstract July 2018

The Influence of Intravitreal Ranibizumab on Aqueous Cytokine Concentrations in Diabetic Macular Edema

Sanjeewa Wickremasinghe; Sivashanth Gnanasekaran; Esther Bandala-Sanchez; Maria Kolic; Sophie Rogers; Annie McAuley; Sukhpal Singh Sandhu; Lyndell L Lim

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4839.

ARVO Annual Meeting Abstract July 2018

Five year outcomes of the Bevordex Study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone).

Elisa Eleanor Cornish; Kelvin Yi Chong Teo; Mark C Gillies; Lyndell L Lim; Ian McAllister; Sutha Sanmugasundram; Vuong Nguyen; Sanjeewa Wickremasinghe; Hemal Mehta; Samantha Fraser-Bell

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4847.

ARVO Annual Meeting Abstract September 2016

Progression of Diabetic Retinopathy in the Bevordex study: a randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema

Lyndell L Lim; Dania Qatarneh; Lauren Hodgson; Hemal Mehta; Sanjeewa Wickremasinghe; Anna Campain; Mark C Gillies; Samantha Fraser-Bell

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2106.

ARVO Annual Meeting Abstract April 2014

Prospective Randomised Trial of Intravitreal Bevacizumab vs. Triamcinolone for Patients with Diabetic Macular Edema at the Time of Cataract Surgery (The DiMECAT Trial)

Lyndell L Lim; Sukhpal Singh Sandhu; Marios Constantinou; Julie Morrison; Sanjeewa Wickremasinghe; Ryo Kawasaki; Salmaan H Qureshi

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1746.

ARVO Annual Meeting Abstract April 2014

VEGF levels in serum and the outcome of intravitreal anti-VEGF treatment in neovascular age-related macular degeneration

Farshad Abedi; Sanjeewa Wickremasinghe; Amirul Islam; Robyn H Guymer

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):592.

ARVO Annual Meeting Abstract April 2014

Qualitative OCT Appearance and Vision Change in Eyes with Neovascular AMD Treated with Anti-VEGF Drugs

Sanjeewa Wickremasinghe; Farshad Abedi; Sukhpal Singh Sandhu; Amirul Islam; Robyn H Guymer

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3971.

ARVO Annual Meeting Abstract March 2012

Gene Variants in the HTRA1 and ARMS2 genes and Outcome of Anti-VEGF Treatment in Neovascular AMD

Farshad Abedi; Sanj Wickremasinghe; Andrea J. Richardson; FM Amirul Islam; Robyn Guymer; Paul N. Baird

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2931.

ARVO Annual Meeting Abstract March 2012

Comparison of macular parameters among keratoconic, myopic and non-myopic individuals using Optical Coherence Tomography

Srujana Sahebjada; Paul Baird; Amirul Islam; Sanj Wickremasinghe

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2104.

Retina January 2012

Retinal Venular Caliber Predicts Visual Outcome after Intravitreal Ranibizumab Injection Treatments for Neovascular AMD

PDF

Sanjeewa S. Wickremasinghe; Lucy Busija; Robyn H. Guymer; Tien Y. Wong; Salmaan Qureshi
TAGS: diameter, exudative age-related macular degeneration, eye, ranibizumab, vision, visual acuity, choroidal neovascularization
Invest. Ophthalmol. Vis. Sci.. 2012; 53(1):37-41. https://doi.org/10.1167/iovs.11-7689

Retina June 2011

Variants in the APOE Gene Are Associated with Improved Outcome after Anti-VEGF Treatment for Neovascular AMD

PDF

Sanjeewa S. Wickremasinghe; Jing Xie; Jonathan Lim; Devinder S. Chauhan; Luba Robman; Andrea J. Richardson; Gregory Hageman; Paul N. Baird; Robyn Guymer
TAGS: anti-vascular endothelial growth factor therapy, apolipoprotein e, exudative age-related macular degeneration, genes, treatment outcome, alleles
Invest. Ophthalmol. Vis. Sci.. 2011; 52(7):4072-4079. https://doi.org/10.1167/iovs.10-6550

ARVO Annual Meeting Abstract April 2011

Do VEGF Gene Variants Contribute To The Treatment Outcomes Of Intravitreal Anti-VEGF Treatment In Patients With Neovascular Age-related Macular Degeneration?

Farshad Abedi; Sanj Wickremasinghe; Andrea J. Richardson; Lucy Busija; Paul Baird; Robyn Guymer

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3067.

ARVO Annual Meeting Abstract April 2011

Qualitative Appearance of OCT Predicts Visual Outcome at 12 months Following Anti-VEGF Therapy for Neovascular AMD

Sukhpal S. Sandhu; Sanjeewa S. Wickremasinghe; Lucy Basija; Jonathan H. Lim; Robyn H. Guymer

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5927.

ARVO Annual Meeting Abstract April 2009

The Prevalence of Idiopathic Macular Telangiectasia Type 2 (IMT): The Melbourne Collaborative Cohort Study

K. Aung; S. S. Wickremasinghe; G. Makeyeva; L. Robman; R. H. Guymer

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):749.

ARVO Annual Meeting Abstract April 2009

Predictors of Treatment Outcomes With Anti-Vascular Endothelial Growth Factor in Neovascular Age-Related Macular Degeneration

J. H. Lim; S. S. Wickremasinghe; D. S. Chauhan; J. Xie; L. D. Robman; A. J. Richardson; P. N. Baird; R. H. Guymer

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):1892.

Clinical Trials November 2008

Retinal Vascular Caliber Changes after Intravitreal Triamcinolone Treatment for Diabetic Macular Edema

PDF

Sanjeewa S. Wickremasinghe; Sophie L. Rogers; Mark C. Gillies; Meidong Zhu; Tien Y. Wong
TAGS: diabetic macular edema, retinal vascular caliber, triamcinolone, eye, diameter, visual acuity
Invest. Ophthalmol. Vis. Sci.. 2008; 49(11):4707-4711. https://doi.org/10.1167/iovs.08-1678

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Predicting Late Age-Related Macular Degeneration Development: Clinical Performance With Multimodal Imaging and Comparison to a Prediction Model

Phase 1 Study of an Intravitreal Axitinib Hydrogel-based Implant for the Treatment of Neovascular Age-Related Macular Degeneration (nAMD)

The DiMECat Trial: A Prospective, Randomised Clinical Trial Of Intravitreous Bevacizumab vs. Triamcinolone in Patients With Diabetic Macular Oedema At The Time Of Cataract Surgery – 12 Month Results

The Influence of Intravitreal Ranibizumab on Inflammation-associated Cytokine Concentrations in Eyes With Diabetic Macular Edema

The DiMECat Trial: A Prospective, Randomised Clinical Trial Of Intravitreous Bevacizumab vs. Triamcinolone In Patients With Diabetic Macular Oedema At The Time Of Cataract Surgery – 6 Month Results

The Influence of Intravitreal Ranibizumab on Aqueous Cytokine Concentrations in Diabetic Macular Edema

Five year outcomes of the Bevordex Study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone).

Progression of Diabetic Retinopathy in the Bevordex study: a randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema

Prospective Randomised Trial of Intravitreal Bevacizumab vs. Triamcinolone for Patients with Diabetic Macular Edema at the Time of Cataract Surgery (The DiMECAT Trial)

VEGF levels in serum and the outcome of intravitreal anti-VEGF treatment in neovascular age-related macular degeneration

Qualitative OCT Appearance and Vision Change in Eyes with Neovascular AMD Treated with Anti-VEGF Drugs

Gene Variants in the HTRA1 and ARMS2 genes and Outcome of Anti-VEGF Treatment in Neovascular AMD

Comparison of macular parameters among keratoconic, myopic and non-myopic individuals using Optical Coherence Tomography

Retinal Venular Caliber Predicts Visual Outcome after Intravitreal Ranibizumab Injection Treatments for Neovascular AMD

Variants in the APOE Gene Are Associated with Improved Outcome after Anti-VEGF Treatment for Neovascular AMD

Do VEGF Gene Variants Contribute To The Treatment Outcomes Of Intravitreal Anti-VEGF Treatment In Patients With Neovascular Age-related Macular Degeneration?

Qualitative Appearance of OCT Predicts Visual Outcome at 12 months Following Anti-VEGF Therapy for Neovascular AMD

The Prevalence of Idiopathic Macular Telangiectasia Type 2 (IMT): The Melbourne Collaborative Cohort Study

Predictors of Treatment Outcomes With Anti-Vascular Endothelial Growth Factor in Neovascular Age-Related Macular Degeneration

Retinal Vascular Caliber Changes after Intravitreal Triamcinolone Treatment for Diabetic Macular Edema

To View More...

You must be signed into an individual account to use this feature.